Treatment of Non-Small Cell Lung Cancer with HER2 Alterations
HER2 alterations are divided into 3 categories: gene mutation, gene amplification, and protein overexpression. Unlike breast and gastric cancers, where gene amplification and protein overexpression are therapeutic targets, genetic mutations are more likely to be therapeutic targets in NSCLC. There have been few effective treatments for NSCLC with HER2 alterations, but in recent years, TKIs such as pyrotinib and poziotinib, and ADCs such as trastuzumab-deruxtecan(T-Dxd)have shown meaningful anti-tumor efficacy. In particular, T-Dxd received FDA approval in August 2022 for NSCLC patients with certain types of mutations in HER2 gene, and is expected to provide new treatment options in the future.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Gan to kagaku ryoho. Cancer & chemotherapy - 50(2023), 7 vom: 02. Juli, Seite 768-772 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Takakura, Toshiaki [VerfasserIn] |
|---|
| Themen: |
Cancer Vaccines |
|---|
| Anmerkungen: |
Date Completed 28.07.2023 Date Revised 28.07.2023 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM359962246 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359962246 | ||
| 003 | DE-627 | ||
| 005 | 20231226082006.0 | ||
| 007 | tu | ||
| 008 | 231226s2023 xx ||||| 00| ||jpn c | ||
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM359962246 | ||
| 035 | |a (NLM)37496218 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Takakura, Toshiaki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment of Non-Small Cell Lung Cancer with HER2 Alterations |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 28.07.2023 | ||
| 500 | |a Date Revised 28.07.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a HER2 alterations are divided into 3 categories: gene mutation, gene amplification, and protein overexpression. Unlike breast and gastric cancers, where gene amplification and protein overexpression are therapeutic targets, genetic mutations are more likely to be therapeutic targets in NSCLC. There have been few effective treatments for NSCLC with HER2 alterations, but in recent years, TKIs such as pyrotinib and poziotinib, and ADCs such as trastuzumab-deruxtecan(T-Dxd)have shown meaningful anti-tumor efficacy. In particular, T-Dxd received FDA approval in August 2022 for NSCLC patients with certain types of mutations in HER2 gene, and is expected to provide new treatment options in the future | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Cancer Vaccines |2 NLM | |
| 650 | 7 | |a Immunoconjugates |2 NLM | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Trastuzumab |2 NLM | |
| 650 | 7 | |a P188ANX8CK |2 NLM | |
| 700 | 1 | |a Yamamoto, Nobuyuki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gan to kagaku ryoho. Cancer & chemotherapy |d 1993 |g 50(2023), 7 vom: 02. Juli, Seite 768-772 |w (DE-627)NLM012601861 |x 0385-0684 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2023 |g number:7 |g day:02 |g month:07 |g pages:768-772 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2023 |e 7 |b 02 |c 07 |h 768-772 | ||